[Chitosan as an adjuvant for parenteral inactivated influenza vaccines].
Addition of 0.5% chitosan derivative to parenteral inactivated influenza vaccines increased antibody titers in the single immunization of mice by 4-5 times while double immunization showed 6-to-10-fold increases as compared with immunization without chitosan. Moreover, chitosan-containing vaccines induced the generation of antibodies to the drift variants of influenza virus. When the mice were given inactivated influenza virus A/H5N2 vaccine containing chitosan, immunogenicity and protective efficacy were much higher than when they received a vaccine containing no chitosan.
Gendon
Iu Z
IuZ
Markushin
S G
SG
Krivtsov
G G
GG
Akopova
I I
II
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D048271:Chitosan / Q000008:administration & dosage* / Q000276:immunology; D003429:Cross Reactions; D040961:Genetic Drift; D007114:Immunization; D007115:Immunization Schedule; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000276:immunology; D053125:Influenza A Virus, H5N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D048271:Chitosan